FCM
BLUE

Farallon Capital Management’s bluebird bio BLUE Stock Holding History

Farallon Capital Management’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$2.76M – 177
2023
Q4 		$2.76M Buy
+100,000
New +$6.1M 0.01% 98

Other funds holding BLUE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Farallon Capital Management's BLUE Position: Q1 2024 in Review

Farallon Capital Management sold out of bluebird bio (BLUE) in Q1 2024, closing a stake of 100,000 shares — an estimated $2.76M sold.

Farallon Capital Management first reported a position in BLUE in Q4 2023 and held it in 1 quarter. The position peaked at $2.76M in Q4 2023. 158 funds tracked by Wall St. Rank hold BLUE as of Q1 2024.

  • Farallon Capital Management reported no remaining bluebird bio position as of Q1 2024 after selling out during the quarter.
  • Farallon Capital Management sold 100,000 bluebird bio shares in Q1 2024, an estimated $2.76M.
  • Farallon Capital Management first reported a position in bluebird bio in Q4 2023 and held it in 1 quarter.
  • Farallon Capital Management's bluebird bio position peaked at $2.76M in Q4 2023.
  • 158 funds tracked by Wall St. Rank held bluebird bio as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.